Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas

7 Apr 2019

Abstract excerpt

BACKGROUND: Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair-mutated phenotypes. The rationale for their use, however, is based on case reports and studies with other types of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31832212
DOI: 10.1093/nop/npz016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomasPMID 31832212Read ↗

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaSemantic proximity Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.Semantic proximity Read ↗

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.Semantic proximity Read ↗

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.Semantic proximity Read ↗

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Semantic proximity Read ↗

Hypermutations in gliomas: a potential immunotherapy target.Semantic proximity Read ↗

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter StudySemantic proximity Read ↗

A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating CellsSemantic proximity Read ↗

Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.Semantic proximity Read ↗

Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.Semantic proximity Read ↗

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.